





INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>			ATTY. DOCKET NO. PC10228A			SERIAL NO. 09/443,542		
			APPLICANT Farzan Rastinejad et al.					
			FILING DATE November 19, 1999			GROUP 1614		
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL	DOCUMENT NUMBER			DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
								
FOREIGN PATENT DOCUMENTS								
DOCUMENT NUMBER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
								YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
<i>J</i>		M. Hollstein et al., "Database of p53 gene somatic mutations in human tumors and cell lines", Nucleic Acids Research, vol. 22, p. 3551-3555, (1994)						
<i>O</i>		P.M. O'Connor et al., "Characterization of the p53 Tumor Suppressor Pathway in Cell Lines of the National Cancer Institute Anticancer Drug Screen and Correlations with the Growth Inhibitory Potency of 123 Anticancer Agents", Cancer Research, vol. 57, p. 4285-4300 (1997)						
<i>g</i>		A. N. Bullock et al., "Rescuing The Function of Mutant p53", Nature Reviews, vol. 1, pp. 68-76, (2001)						
<i>g</i>		Martin L. Smith et al., "Chemotherapeutic Targeting of p53", Cancer Biology & Therapy, Internet pre-published on Sept. 5, 2001 as Manuscript MS # 08-30-02						
<i>J</i>		Jackson B. Gibbs, "Mechanism-Based Target Identification and Drug Discovery in Cancer Research", Science Magazine, vol. 287, pp-1969-1973 (2000)						
<i>J</i>		Elizabeth Pennisi, "Bracing p53 for the War on Cancer", Science Magazine, vol. 286, p. 2431 (1999)						
<i>J</i>		Rishu Takimoto et al., "The Mutant p53 Conformation Modifying Drug, CP-31398, Can Induce Apoptosis of Human Cancer Cells and can Stabilize Wild-Type p53 Protein", Cancer Biology & Therapy, Internet pre-published on September 4, 2001 as Manuscript MS# 08-08-01						
<i>O</i>		Barbara A. Foster et al., Science Magazine, "Pharmacological Rescue of Mutant p53 Conformation and Function", vol. 286, pp.2507-2510 (1999)						
<i>J</i>		Craig Caldwell et al., "The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth", Gene, vol. 277 pp. 15-30 (2001)						
<i>J</i>		The Journal of Antibiotics, Lucilactaene, a New Cell Cycle Inhibitor in p53-Transfected Cancer Cells", vol. 54, pp. 850-854 (2001)						
<i>J</i>		Jun-Li Luo, et al "UV-induced DNA Damage and Mutations in Hupki (Human p53 Knock-in) Mice Recapitulate p53 Hotspot Alterations in Sun-exposed Human Skin", Cancer Research, vol. 61, pp. 8158-8163 (2001)						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
EXAMINER			DATE CONSIDERED					
								

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>			ATTY. DOCKET NO. PC10228A				SERIAL NO. 09/443,542						
			APPLICANT Farzan Rastinejad et al.										
			FILING DATE November 19, 1999				GROUP 1614						
U.S. PATENT DOCUMENTS													
EXAMINER INITIAL		DOCUMENT NUMBER					DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
FOREIGN PATENT DOCUMENTS													
DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
			Vladimir J.N. Bykov, et al., "Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound", Nature Medicine, vol. 8, pp. 282-288 (March 2002)										
EXAMINER 			DATE CONSIDERED 										
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													